A novel chimeric DNA vaccine: Enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene

Molecular Medicine Reports

Volumn 4, Issue 5, 2011, Pages 885-890

  Choi, Dae Han ^a   Woo, Jong Kyu ^a   Choi, Yun ^a   Seo, Hye Sook ^b   Kim, Chul Woo ^a  

^a Seoul National University   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Cancer; Chimeric DNA vaccine; HSP70; Immunotherapy; Muc1

Indexed keywords

DNA VACCINE; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; MUCIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MELANOMA B16; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN SECRETION; WESTERN BLOTTING;

ANIMALS; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNITY; MICE; MICE, INBRED C57BL; MUCIN-1; NEOPLASMS; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION; VACCINES, DNA;

MUS;

EID: 79960412308     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.525     Document Type: Article

References (25)

1. Yannelli JR and Wroblewski JM: On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23: 97-113, 2004. (Pubitemid 39446365)
2. Fioretti D, Iurescia S, Fazio VM and Rinaldi M: DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol: Mar 28, 2010 (E-pub ahead of print).
3. Ferrone CR, Perales MA, Goldberg SM, et al: Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 12: 5511-5519, 2006. (Pubitemid 44497268)
4. Ruffini PA, Grodeland G, Fredriksen AB and Bogen B: Human chemokine MIP1alpha increases efficiency of targeted DNA fusion vaccines. Vaccine: Nov 4, 2010 (E-pub ahead of print).
5. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchell J: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823, 1988.
6. Vlad AM, Kettel JC, Alajez NM, Carlos CA and Finn OJ: MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82: 249-293, 2004. (Pubitemid 38209513)
7. Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA and Harris A: Identification of MUC1 proteolytic cleavage sites in vivo. Biochem Biophys Res Commun 283: 715-720, 2001. (Pubitemid 32917949)
8. Srivastava P: Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2: 185-194, 2002.
9. Chen CH, Wang TL, Hung CF, et al: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042, 2000.
10. Cho BK, Palliser D, Guillen E, et al: A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 12: 263-272, 2000.
11. Castelli C, Ciupitu AM, Rini F, et al: Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 61: 222-227, 2001. (Pubitemid 32095721)
12. Binder RJ and Srivastava PK: Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 6: 593-599, 2005. (Pubitemid 41710730)
13. Jeon YH, Choi Y, Yoon SO, Kim CW and Chung JK: Synergistic tumoricidal effect of combined hMUC1 vaccination and hNIS radioiodine gene therapy. Mol Cancer Ther 7: 2252-2260, 2008.
14. Cho JA, Yeo DJ, Son HY, et al: Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int J Cancer 114: 613-622, 2005.
15. Fong CL, Mok CL and Hui KM: Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression. Gene Ther 13: 245-256, 2006. (Pubitemid 43148647)
16. Fredriksen AB, Sandlie I and Bogen B: DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther 13: 776-785, 2006.
17. Schjetne KW, Fredriksen AB and Bogen B: Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol 178: 4169-4176, 2007. (Pubitemid 46492367)
18. Fredriksen AB and Bogen B: Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood 110: 1797-1805, 2007. (Pubitemid 47443890)
19. Nchinda G, Kuroiwa J, Oks M, et al: The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 118: 1427-1436, 2008. (Pubitemid 351500436)
20. Heukamp LC, van Hall T, Ossendorp F, et al: Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 25: 46-56, 2002. (Pubitemid 34052833)
21. Chu Y, Xia M, Lin Y, et al: Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther 13: 510-519, 2006.
22. Snyder LA, Goletz TJ, Gunn GR, et al: A MUC1/IL-18 DNA vaccine induces antitumor immunity and increased survival in MUC1 transgenic mice. Vaccine 24: 3340-3352, 2006.
23. Hauser H and Chen SY: Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 31: 225-231, 2003. (Pubitemid 37162795)
24. Hauser H, Shen L, Gu QL, Krueger S and Chen SY: Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 11: 924-932, 2004. (Pubitemid 38786607)
25. Millar DG, Garza KM, Odermatt B, et al: Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat Med 9: 1469-1476, 2003. (Pubitemid 38004773)